Complicated diagnostics of primary sclerosing cholangitis in a patient with recurrent episodes of acute bacterial cholangitis
Authors:
L. Douda 1; R. Keil 1; J. Lochmannová 1; J. Drábek 1; O. Fabián 2; L. Hornofová 2; E. Honsová 3; M. Jirsa⁴
Authors‘ workplace:
Interní klinika 2. LF UK a FN v Motole, Praha
1; Ústav patologie a molekulární medicíny, 2. LF UK a FN v Motole, Praha
2; Pracoviště klinické a transplantační patologie, Transplacentrum, IKEM, Praha
3; Centrum experimentální medicíny, IKEM, Praha
4
Published in:
Gastroent Hepatol 2015; 69(4): 368-375
Category:
Clinical and Experimental Gastroenterology: Case Report
doi:
https://doi.org/10.14735/amgh2015368
Overview
Acute bacterial cholangitis is one of the possible complications of primary sclerosing cholangitis and in some cases it can occur as a fulminant cholangiogenic sepsis with septic shock and multiple organ dysfunction syndrome. The authors describe a case of a 39-year‑ old man where the primary sclerosing cholangitis manifested as recurrent episodes of acute bacterial cholangitis, including one with a life‑ threatening consequences. The diagnostic and therapeutic method of choice an urgent endoscopic retrograde cholangiopancreatography with a decompression of the biliary tree and subsequent targeted antibiotic therapy. The diagnosis of primary sclerosing cholangitis can sometimes be difficult, as it was in our case, due to insufficient histologic verification and intercurrent clinical complications.
Key words:
primary sclerosing cholangitis – acute bacterial cholangitis – cholangiogenic sepsis – endoscopic retrograde cholangiography
The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.
Submitted:
12. 8. 2014
Accepted:
11. 1. 2015
Sources
1. Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis 1993; 13(3): 261– 275.
2. Bergquist A, Montgomery SM, Bahmanyar S et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first‑ degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6(8): 939– 943. doi: 10.1016/ j.cgh.2008.03.016.
3. Prochazka EJ, Terasaki PI, Park MS et al. Association of primary sclerosing cholangitis with HLA‑DRw52a. N Engl J Med 1990; 322(26): 1842– 1844.
4. Zetterquist H, Broomé U, Einarsson K et al. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA‑DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992; 33(7): 942– 946.
5. Norris S, Kondeatis E, Collins R et al. Mapping MHC‑ encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001; 120(6): 1475– 1482.
6. Janse M, Lamberts LE, Franke L et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011; 53(6): 1977– 1985. doi: 10.1002/ hep.24307.
7. Melum E, Franke A, Schramm C et al. Genome‑ wide association analysis in primary sclerosing cholangitis identifies two non‑HLA susceptibility loci. Nat Genet 2011; 43(1): 17– 19. doi: 10.1038/ ng.728.
8. Hov JR, Keitel V, Laerdahl JK et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 2010; 5(8): e12403. doi: 10.1371/ journal.pone.0012403.
9. Molodecky NA, Kareemi H, Parab R et al. Incidence of primary sclerosing cholangitis: a systematic review and meta‑analysis. Hepatology 2011; 53(5): 1590– 1599. doi: 10.1002/ hep.24247.
10. Wienser RH, Porayko MK, LaRusso NF et al. Diseases of the Liver. 7th ed. Philadelphia: JB Lippincott 1993: 411.
11. Vierling JM. Hepatobiliary complications of ulcerative colitis and Crohn‘s disease. In: Zakim D, Boyer TD, WB Saunders (eds). Hepatology: a textbook of liver disease. Vol 2. Philadelphia 1996: 1366.
12. Porayko MK, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis: a progressive disease? Semin Liver Dis 1991; 11(1): 18– 25.
13. Sokol H, Cosnes J, Chazouilleres O et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008; 14(22): 3497– 3503.
14. Drastich P, Kamenář DE, Wohl P et al. Ulcerative colitis in patiens with primary sclerosing cholangitis (PSC‑ UC) – a specific subgroup. Čes a Slov Gastroent a Hepatol 2007; 61 (Suppl 1).
15. Loftus EV Jr., Harewood GC, Loftus C et al. PSC‑ IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54(1): 91– 96.
16. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332(14): 924– 933.
17. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985; 102(5): 581– 587.
18. Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51(2): 660– 678. doi: 10.1002/ hep.23294.
19. Dave M, Elmunzer BJ, Dwamena BA et al. Primary sclerosing cholangitis: meta‑analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010; 256(2): 387– 396. doi: 10.1148/ radiol. 10091953.
20. Berstad AE, Aabakken L, Smith HJ et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006; 4(4): 514– 520.
21. Angulo P, Pearce DH, Johnson CD et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000; 33(4): 520– 527.
22. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003; 98(5): 1155– 1158.
23. Tischendorf JJ, Hecker H, Kruger M et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007; 102(1): 107– 114.
24. Broome U, Olsson R, Loof L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38(4): 610– 615.
25. Chapman RW, Arborgh BA, Rhodes JM et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21(10): 870– 877.
26. van Milligen de Wit AW, van Deventer SJ, Tytgat GN. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995; 90(6): 893– 900.
27. Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008; 14(24): 3781– 3791.
28. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11(1): 31– 39.
29. Tung BY, Brentnall T, Kowdley KV et al. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (abstract). Hepatology 1996; 24: 169A.
30. Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125(5): 1364– 1369.
31. Escorsell A, Parés A, Rodés J et al. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994; 21(5): 787– 791.
32. Jørgensen KK, Grzyb K, Lundin KE et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012; 18(3): 536– 545. doi: 10.1002/ ibd.21699.
33. Olsson R, Danielsson A, Jarnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100 (5 Pt 1): 1319– 1323.
34. Kaplan GG, Laupland KB, Butzner D et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population‑based analysis. Am J Gastroenterol 2007; 102(5): 1042– 1049.
35. Rasmussen HH, Fallingborg JF, Mortensen PB et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn‘s disease. Scand J Gastroenterol 1997; 32(6): 604– 610.
36. Rosen CB, Nagorney DM, Wiesner RH et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213(1): 21– 25.
37. Jørgensen KK, Grzyb K, Lundin KE et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2011; 18(3): 536– 545. doi: 10.1002/ ibd.21699.
38. Lindström L, Hultcrantz R, Boberg KM et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013; 11(7): 841– 846. doi: 10.1016/ j.cgh.2012.12.032.
39. Préaux AM, Mallat A, Rosenbaum J et al. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast‑like cells. Hepatology 1997; 26(2): 315– 322.
40. Bharucha AE, Jorgensen R, Lichtman SN et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95(9): 2338– 2342.
41. Schramm C, Schirmacher P, Helmreich‑ Becker I et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999; 131(12): 943– 946.
42. van Hoogstraten HJ, Vleggaar FP, Boland GJ et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double‑blind pilot study. BelgianDutch PSC Study Group. Am J Gastroenterol 2000; 95(8): 2015– 2122.
43. Farkkila MA, Karkkainen P, Karvonen AL et al. Combination of ursodeoxycholic acid (UDCA) and metronidazole (MTZ) in PSC: reduction of inflammation in liver correlates with the decrease of the New Mayo Risk Score (abstract). Gastroenterology 2003; 124: A707.
44. Lichtman SN, Sartor RB, Keku J et al. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98(2): 414– 423.
45. Färkkilä M, Karvonen AL, Nurmi H et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo‑ controlled trial. Hepatology 2004; 40(6): 1379– 1386.
46. Davies YK, Cox KM, Abdullah BA et al. Long‑term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47(1): 61– 67. doi: 10.1097/ MPG.0b013e31816fee95.
47. Silveira MG, Torok NJ, Gossard AA et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009; 104(1): 83– 88. doi: 10.1038/ ajg.2008.14.
48. Tabibian JH, Weeding E, Jorgensen RA et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis – a pilot study. Aliment Pharmacol Ther 2013; 37(6): 604– 612. doi: 10.1111/ apt.12232.
49. MacCarty RL, LaRusso NF, Wiesner RH et al. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983; 149(1): 39– 44.
50. May GR, Bender CE, LaRusso NF et al. Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. AJR Am J Roentgenol 1985; 145(5): 1061– 1064.
51. Johnson GK, Geenen JE, Venu RP et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 1991; 37(1): 38– 43.
52. Lee JG, Schutz SM, England RE et al. Endoscopic therapy of sclerosing cholangitis. Hepatology 1995; 21(3): 661– 667.
53. Gaing AA, Geders JM, Cohen SA et al. Endoscopic management of primary sclerosing cholangitis: review, and report of an open series. Am J Gastroenterol 1993; 88(12): 2000– 2008.
54. van Milligen de Wit AW, van Bracht J, Rauws EA et al. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1996; 44(3): 293– 299.
55. Papatheodoridis GV, Hamilton M, Mistry PK et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43(5): 639– 644.
56. Bergman JJ. Management of postsurgical bile leaks and bile duct strictures. In: Cotton PB (ed.). ERCP. GastroHep eBook 2008.
57. Larghi A, Tringali A, Lecca PG et al. Management of biliary strictures. Am J Gastroenterol 2008; 103(2): 458– 473.
58. vanMilligen deWitt AW, Rauws EA, vanBracht J et al. Lack of complications for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997; 46(4): 344– 347.
59. Ponsioen CY, Lam K, vanMiligen deWitt AW et al. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999; 94(9): 2403– 2407.
60. Pawlik TM, Olbrecht VA, Pitt HA et al. Primary sclerosing cholangitis: role of extrahepatic biliary resection. J Am Coll Surg 2008; 206(5): 822– 830. doi: 10.1016/ j.jamcollsurg.2007.12.015.
61. Drastich P, Bajer L, Wohl P et al. Transplantace jater pro primární sklerozující cholangitidu. Gastroent Hepatol 2013; 67(5): 413– 420.
62. Langnas AN, Grazi GL, Stratta RJ et al. Primary sclerosing cholangitis: the emerging role for liver transplantation. Am J Gastroenterol 1990; 85(9): 1136– 1141.
63. McEntee G, Wiesner RH, Rosen C et al. A comparative study of patients undergoing liver transplantation for primary sclerosing cholangitis and primary biliary cirrhosis. Transplant Proc 1991; 23(1 Pt 2): 1563– 1564.
64. Graziadei IW, Wiesner RH, Marotta PJet al. Long‑term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30(5): 1121– 1127.
65. Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009; 29(1): 3– 18. doi: 10.1055/ s‑ 0029‑ 1192052.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2015 Issue 4
Most read in this issue
- Unusual cause of diarrhoea – cholecystocolic fistula: case interpretation and overview of literature
- Budenofalk Uno 9 mg gastro‑resistant granules
- Diagnosis and treatment of anemia in patients with diseases of the gastrointestinal tract
- Middle generation of gastroenterologists and hepatologists